What is Exon Skipping Therapy in Duchenne Muscular Dystrophy and How Does it Work?

What is exon skipping therapy in DMD, and how does it work in Duchenne muscular dystrophy? This innovative genetic approach targets faulty exons to help restore dystrophin production. Understanding exon skipping therapy in Duchenne muscular dystrophy is key to navigating modern treatment options.

By correcting the reading frame, exon skipping therapy in Duchenne muscular dystrophy offers a personalized strategy for eligible patients. Discover how does it work, who can benefit, and why it is reshaping DMD care.

The Importance of Dystrophin

As you know, the dystrophin gene in Duchenne muscular dystrophy is the longest gene in the human body and contains 79 exons. These exons are arranged sequentially, like train wagons, reaching the 79th wagon at the end. In this way, the body produces dystrophin, which helps maintain and protect muscle function. Read More: What is dystrophin gene?

- Follow Us -

When one or more of these exons are missing, it may not be possible to reach the 79th exon because there is a disruption in the sequence. However, not every exon deletion causes this problem. There is also a milder form of the disease called Becker muscular dystrophy (BMD), which is associated with a longer life expectancy. By understanding the sequence of the dystrophin gene, it becomes clearer how this is possible.

What is Exon Skipping?

Exon skipping is a molecular technique designed to “skip over” faulty sections (exons) of the dystrophin gene during mRNA processing. Duchenne muscular dystrophy is caused by mutations in the DMD gene, one of the largest genes in the human genome. These mutations often disrupt the reading frame, leading to a complete absence of functional dystrophin protein.

Exon skipping uses antisense oligonucleotides (AONs)—short synthetic RNA-like molecules—to bind specific sequences in the pre-mRNA. This binding masks targeted exons from the cellular splicing machinery, effectively removing them from the final mRNA transcript.

Key Concept:

• Out-of-frame mutation → No dystrophin (DMD)
• Restored reading frame via exon skipping → Shortened but functional dystrophin (Becker-like phenotype)

This approach essentially converts a severe Duchenne phenotype into a milder Becker muscular dystrophy-like condition. Read More: Becker vs Duchenne

What happens in Becker muscular dystrophy?

To explain this situation, let’s take a closer look at the region between exons 39 and 44.

In Becker muscular dystrophy, an exon may be deleted; for example, exon 42 may be missing, as in our case. Read More: What is Exon Deletion in DMD?

Even if part of the gene is missing, exon 41 can join exon 43, allowing the sequence to continue to the end of the gene. The key point here is the junction between the two exons. You can think of it like a puzzle.

Exon deletions can cause Duchenne muscular dystrophy (DMD), but which exon is deleted is important. As shown in the example above, exon 42 is deleted, yet exons 41 and 43 can still connect, allowing the sequence to continue. In such cases, the patient is usually diagnosed with Becker muscular dystrophy (BMD). In BMD, the disease typically presents with milder symptoms, and patients can often walk into their 40s or 50s.

What happens in Duchenne muscular dystrophy?

In Duchenne muscular dystrophy (DMD), one or more exons are deleted, preventing the remaining parts of the gene from being properly spliced together. In the example below (using exons 39–44), let’s assume that exon 43 is deleted.

If exon 43 is deleted, as in our example, exons 42 and 44 cannot connect or join properly. This disrupts the continuity of the exon sequence and alters the reading frame. As a result, the dystrophin protein cannot be produced correctly. This genetic disorder impairs muscle function and maintenance.

How Does Exon Skipping Therapy Work in DMD?

Exon skipping therapy is a targeted treatment approach for Duchenne muscular dystrophy (DMD), a genetic condition that causes progressive muscle weakness.

This therapy works by using small, lab-made molecules to “skip over” specific faulty sections (called exons) of the dystrophin gene during protein production. By skipping the damaged exon, the gene’s instructions can be read more accurately, allowing the body to produce a shorter but more functional version of dystrophin.

While exon skipping therapy does not cure Duchenne muscular dystrophy, it can help slow muscle degeneration and may improve muscle function in individuals with certain genetic mutations. Because it targets specific exons, genetic testing is required to determine who may benefit. Overall, exon skipping represents a more personalized, gene-focused approach to treating DMD and is an important step forward in neuromuscular care.

With exon skipping therapy, exon 42 can join exon 45, allowing the rest of the protein to be produced.

Learn More: Development and future prospects of exon-skipping

Variant-Specific Therapies in DMD

Potential Duchenne Population Amenable for Exon Skipping

You should carefully review the table above based on your genetic test result. For example, if your report shows a deletion of exons 42 and 43, you should follow studies related to exon 44 skipping therapy. > Read More: Next Generation Exon Skipping Therapies

FAQ: Exon Skipping in Duchenne Muscular Dystrophy

Final Thoughts

Exon skipping therapy in Duchenne muscular dystrophy marks a major step in precision medicine. It targets the genetic cause rather than symptoms. While not a cure, it offers meaningful functional benefits. Eligibility depends on specific mutations. Early diagnosis improves treatment impact. Access and cost remain global challenges. Research is rapidly advancing new options. Combination approaches may enhance outcomes. Families should seek expert genetic guidance. Overall, exon skipping therapy in Duchenne muscular dystrophy brings realistic hope for better disease management.

Learn More: Duchenne Exon Skipping Treatment Search Tool

- Follow Us -